<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517916</url>
  </required_header>
  <id_info>
    <org_study_id>630-0029-01</org_study_id>
    <nct_id>NCT04517916</nct_id>
  </id_info>
  <brief_title>Zephyr Etude Post-Inscription (French Registry)</brief_title>
  <official_title>Zephyr Etude Post-Inscription (French Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonx Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonx Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Registry is to provide ongoing safety and effectiveness assessment of&#xD;
      the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease&#xD;
      (COPD) Grade III and Grade IV in order to support the renewal of the inscription of the&#xD;
      Zephyr Valve on the list LPPR (Art 165-1) in France.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, single-arm, prospective Registry to be conducted at a minimum of 12&#xD;
      study centers. Approximately 150 patients with severe emphysema undergoing Zephyr Valve&#xD;
      treatment will be enrolled and followed out to 3 years. Assessments will be performed at&#xD;
      45-days, 6-months, 12-months, 24-months and 36-months post-procedure.&#xD;
&#xD;
      Patients prescribed the Zephyr Valve treatment will be consented and will be enrolled only&#xD;
      after determination of little to no collateral ventilation between target and ipsilateral&#xD;
      lobes. Safety and effectiveness of the Zephyr Valve treatment will be evaluated&#xD;
      post-treatment based on data collected out to 3-years post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>12 months</time_frame>
    <description>The percent of patients achieving an improvement in the post-bronchodilator FEV1 of ≥12% at 12-months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treated Lobar Volume Reduction (TLVR)</measure>
    <time_frame>45 days</time_frame>
    <description>Treated Lobar Volume Reduction (TLVR) assessed by High Resolution Computed Tomography (HRCT) at 45-days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Absolute Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator</measure>
    <time_frame>Baseline, 6-months, 12-months, 24-months and 36-months</time_frame>
    <description>Absolute Change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator</measure>
    <time_frame>Baseline, 6-months, 12-months, 24-months and 36-months</time_frame>
    <description>Percent change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in Residual Volume (RV)</measure>
    <time_frame>Baseline, 6-months, 12-months, 24-months and 36-months</time_frame>
    <description>Absolute Change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Residual Volume (RV)</measure>
    <time_frame>Baseline, 6-months, 12-months, 24-months and 36-months</time_frame>
    <description>Percent change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in St. George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Baseline, 6-months and 12-months</time_frame>
    <description>Absolute change in St. George's Respiratory Questionnaire (SGRQ) from Baseline to 6-months and 12-months.&#xD;
The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in St. George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Baseline, 6-months and 12-months</time_frame>
    <description>Percent change in St. George's Respiratory Questionnaire (SGRQ) Total Score from Baseline to 6-months and 12-months.&#xD;
The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in Modified Medical Research Council (mMRC)</measure>
    <time_frame>Baseline, 6-months and 12-months</time_frame>
    <description>Absolute Change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months.&#xD;
The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Modified Medical Research Council (mMRC)</measure>
    <time_frame>Baseline, 6-months and 12-months</time_frame>
    <description>Percent change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months.&#xD;
The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Change in Six-Minute Walk Distance (6MWT)</measure>
    <time_frame>Baseline, 6-months and 12-months.</time_frame>
    <description>Absolute change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Six-Minute Walk Distance (6MWT)</measure>
    <time_frame>Baseline, 6-months and 12-months.</time_frame>
    <description>Percent change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Emphysema or COPD</condition>
  <arm_group>
    <arm_group_label>Zephyr Valve treatment</arm_group_label>
    <description>Patients undergoing the Zephyr Valve treatment for emphysema/COPD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zephyr Valve</intervention_name>
    <description>Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.</description>
    <arm_group_label>Zephyr Valve treatment</arm_group_label>
    <other_name>Zephyr System</other_name>
    <other_name>BLVR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an all-comers Registry. Physicians at participating study centers will invite&#xD;
        consecutive patients who are prescribed Zephyr Valve treatment to participate in the&#xD;
        Registry and allow data collection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with emphysema (COPD Grade III and Grade IV) considered appropriate for the&#xD;
             bronchoscopic lung volume reduction procedure by the physician.&#xD;
&#xD;
          -  Subjects who signed an Informed Consent Form to allow data collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects determined to have collateral ventilation between the target(s) and&#xD;
             ipsilateral lobe(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Egenod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Dupuytren (CHRU Limoges)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis McHugh</last_name>
    <role>Study Director</role>
    <affiliation>Pulmonx Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis McHugh</last_name>
    <phone>925 785-5237</phone>
    <email>dmchugh@pulmonx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Mohmood</last_name>
    <phone>650-216-0106</phone>
    <email>nmohmood@pulmonx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie LOUSSOUARN</last_name>
      <phone>+33 6 25 02 41 35</phone>
      <email>aurelie.loussouarn@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe GUT-GOBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Said BELHADJ</last_name>
      <phone>+33 3 80 29 37 72</phone>
      <email>saidfehd.belhadj@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe BONNIAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>LaTronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samarmar CHACAROUN</last_name>
      <phone>+33 4 76 76 64 00</phone>
      <email>schacaroun@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno DEGANO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Aline MOULART</last_name>
      <phone>+33 3 20 44 59 62</phone>
      <email>Marie-Aline.moulart@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Frederic WALLYN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloise DOBBELS</last_name>
      <phone>+33 5 55 05 68 92</phone>
      <email>eloise.dobbels@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas EGENOD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam BOULHAIS</last_name>
      <phone>+33 4 67 33 59 37</phone>
      <email>m-boulhais@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud BOURDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amina BENCHERIF</last_name>
    </contact>
    <investigator>
      <last_name>Armelle MARCEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine LORUT</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas ROCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyne LEFORT</last_name>
      <phone>+33 2 35 59 06 24</phone>
      <email>mlefort@adir-hautenormandie.com</email>
    </contact>
    <investigator>
      <last_name>Samy LACHKAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>St. Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda GBADOE</last_name>
      <phone>+04 77 82 95 32</phone>
      <email>melinda.gbadoe@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel VERGNON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien STAUDER</last_name>
      <phone>+33 3 69 55 06 45</phone>
      <email>romain.kessler@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Romain KESSLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine RIGAL</last_name>
      <phone>+33 5 67 77 17 49</phone>
      <email>rigal.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GUIBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018 Nov 1;198(9):1151-1164. doi: 10.1164/rccm.201803-0590OC.</citation>
    <PMID>29787288</PMID>
  </reference>
  <reference>
    <citation>Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hübner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team *. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017 Dec 15;196(12):1535-1543. doi: 10.1164/rccm.201707-1327OC.</citation>
    <PMID>28885054</PMID>
  </reference>
  <reference>
    <citation>Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, Petermann C, Hubner RH, Stanzel F, Eberhardt R; IMPACT Study Team. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med. 2016 Nov 1;194(9):1073-1082.</citation>
    <PMID>27580428</PMID>
  </reference>
  <reference>
    <citation>Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med. 2015 Dec 10;373(24):2325-35. doi: 10.1056/NEJMoa1507807.</citation>
    <PMID>26650153</PMID>
  </reference>
  <reference>
    <citation>Klooster K, Hartman JE, Ten Hacken NH, Slebos DJ. One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial. Respiration. 2017;93(2):112-121. doi: 10.1159/000453529. Epub 2016 Dec 15.</citation>
    <PMID>27974713</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

